A novel peroxisome proliferator-activated gamma (PPARγ) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential
| Autor: | Jin Cheng, Coleman Gross, Bishwajit Nag, Maya S. Gowri, Gerald M. Reaven, Somesh Sharma, Partha Neogi, Satya Medicherla, Debendranath Dey |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Blood Glucose
Transcriptional Activation medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Mice Obese Receptors Cytoplasmic and Nuclear Peroxisome proliferator-activated receptor Transfection PPAR agonist Rosiglitazone Mice Radioligand Assay Diabetes mellitus genetics Endocrinology Internal medicine Adipocytes Diabetes Mellitus medicine Animals Humans Hypoglycemic Agents Insulin Thiazolidinedione Receptor Glycogen synthase Cells Cultured chemistry.chemical_classification Dose-Response Relationship Drug biology 3T3 Cells Rats Rats Zucker Mice Inbred C57BL Thiazoles Adipose Tissue chemistry biology.protein Thiazolidinediones Pioglitazone Glycogen Transcription Factors medicine.drug |
| Zdroj: | Metabolism. 52:1012-1018 |
| ISSN: | 0026-0495 |
| Popis: | Agonists of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) are pharmacologically active antihyperglycemic agents that act by increasing peripheral tissue sensitivity to insulin. Many of these agonists have antihyperglycemic activity that is directly proportional to their ability to bind and activate PPAR gamma; however, recent data bring this relationship into question. In this report we describe a new PPAR gamma agonist, CLX-0921, that is derived from a natural product. This thiazolidinedione (TZD) has a spectrum of activity that differs from commercially available TZDs. It is a weak activator of PPAR gamma (EC(50) of 0.284 micromol/L) compared to rosiglitazone (EC(50) 0.009 micromol/L). Despite this difference, the drug maintains potent glucose uptake activity in vitro and glucose-lowering activity in vivo that is equipotent to that of rosiglitazone. Moreover, CLX-0921 showed a 10-fold reduction in in vitro adipogenic potential compared to rosiglitazone. CLX-0921 also increases glycogen synthesis, an activity not typically associated with rosiglitazone or pioglitazone. Thus CLX-0921 appears to have a distinct spectrum of activity relative to other TZDs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect